Specijalna Bolnica Za Medicinsku Rehabilitaciju Krapinske Toplice — Clinical Trial Site

18 Registered trials

7 Currently recruiting

Organisation

Specijalna Bolnica Za Medicinsku Rehabilitaciju Krapinske Toplice

Location

Krapinske Toplice, Croatia

Identifier

ORG-100045036

Address

Ulica Ljudevita Gaja 2, 49217, Croatia

Departments

#7005: Cardiovascular rehabilitation
#7023
2104: Cardiology
Cardiac rehabilitation department
Cardiology
Department of intensive medicine with an emergency internist clinic
N/A
NA
Odjel za reanimatologiju i intenzivno lijecenje
Resuscitation and intensive care

Clinical trials at this site (18)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting

2024-520446-31-00 Participants with overweight or obesity, and type 2 dia 5 2026-05-27
AMAZE 2: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight and type 2 diabetes lose wei… Recruiting

2024-520441-23-00 Overweight or obesity, and type 2 diabetes 5 2026-05-13
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatme… Recruiting

2023-508875-35-00 Heart condition 5 2025-09-01
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Weight loss in people living with overweight or obesity and type 2 diabetes following treatment with cagrilintide Ended

2024-519531-41-00 Overweight and obesity 5 2025-10-31
Study to Evaluate Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA 3 Study) Ended

2023-509300-14-00 Severe hypertriglyceridemia (SHTG) 5 2024-10-31
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21